Last updated: 07/17/2024 17:27:39
To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants with Symptoms of Common Cold
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Subjects with Symptoms of Common Cold
Trial description: This study will be conducted in adult participants with symptoms of common cold assessing if 1146A nasal spray reduces the severity of symptoms of the common cold compared to placebo. The study will also evaluate the safety of 1146A compared to placebo.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Average Nasal Symptom Score over Days 1-4 (ANSS1-4)
Timeframe: Up to Day 4 (Day 1 to 4)
Secondary outcomes:
Average Nasal Symptom Score over Days 1-7 (ANSS1-7)
Timeframe: Up to Day 7 (Day 1 to 7)
Average Total Symptom Score over Days 1-4 (ATSS1-4)
Timeframe: Up to Day 4 (Day 1 to 4)
Average Total Symptom Score over Days 1-7 (ATSS1-7)
Timeframe: Up to Day 7 (Day 1 to 7)
Interventions:
Drug: Carbomer 980 (1146A)
Other: Placebo
Enrollment:
171
Observational study model:
Not applicable
Primary completion date:
2017-07-06
Time perspective:
Not applicable
Clinical publications:
Dennie L. Safety and Efficacy of 0.5% Carbomer 980 Gel for Treatment of Symptoms of Common Cold: Results of 2 Randomized Trials. Drugs R D. 2019 Jun;19(2):191-200. doi: 10.1007/s40268-019-0270-3. PMID:31004286
Medical condition
Common cold
Product
GI236825
Collaborators
Not applicable
Study date(s)
December 2016 to June 2017
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18 - 75 years
Accepts healthy volunteers
No
- Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
- Aged between 18 to 75 years inclusive.
- Women who have a positive urine pregnancy test.
- Women who are breast-feeding.
Inclusion and exclusion criteria
Inclusion criteria:
- Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
- Aged between 18 to 75 years inclusive.
- Male or female.
- Good general and mental health with, in the opinion of the Investigator or medically qualified designee no clinically significant and relevant abnormalities in medical history or upon physical and Investigator-led nasal examination.
- Females of childbearing potential who are, in the opinion of the Investigator, practicing a reliable method of contraception. Adequate contraception is defined as abstinence, oral contraceptive, either combined or progestogen alone OR injectable progestogen OR implants of levonorgestrel OR estrogenic vaginal ring OR percutaneous contraceptive patches OR intrauterine device or intrauterine system OR double barrier method (condom or occlusive cap (diaphragm or cervical vault caps) plus spermicidal agent (foam, gel, film, cream, suppository)) OR male partner sterilization prior to the female participant's entry into the study, and this male is the sole partner for that participant.
- Investigator confirmed diagnosis of symptomatic common cold with an onset of less than 48 hours prior to randomization. Symptomatic common cold is defined as TSS > 9 AND a score >1 for at least one of the following symptoms: sore throat, runny nose, or blocked nose.
Exclusion criteria:
- Women who have a positive urine pregnancy test.
- Women who are breast-feeding.
- During the entire study (Screening – last participant visit):
- A. Participant who have used medications or therapies that could interfere with study evaluations and have not had the proper washout period from these medications or therapies or are anticipated to require any concomitant intranasal medication during that period or at any time throughout the study.
- B. Nasal disease(s) likely to affect deposition of intranasal medication, such as chronic sinusitis, rhinitis medicamentosa, clinically significant polyposis, or clinically significant nasal structural abnormalities.
- C. Nasal surgery or sinus surgery within the previous year.
- D. Any condition that prohibits the participant from actuating nasal spray devices (severe rheumatoid arthritis; deformed hands and fingers; missing fingers).
- E. Clinically relevant abnormal physical findings which, in the opinion of the Investigator or sponsor’s medical monitor, would interfere with the objectives of the study or that may preclude compliance with the study procedures.
- F. Uncontrolled cardiovascular, pulmonary, renal, hepatic, gastrointestinal, hematological, endocrine, metabolic, autoimmune, neurological, psychiatric or other diseases at screening that would interfere with the study in the opinion of the Investigator.
- G. Participants with seasonal allergic rhinitis if randomization occurs during their expected allergy season or perennial allergic rhinitis.
- H. Severe COPD, persistent asthma, or recent COPD/asthma exacerbation.
- I. An inability to comprehend and satisfactorily use the measurement instruments as determined by the study sites staff on screening.
- J. Participants with a fever > 38°C (100.4°F).
- K. Frequent uses of analgesics (i.e. have taken an analgesic for pain in headache and pain in muscle/joints for at least 1 dose per week on average over the past 6 months).
- Known or suspected intolerance or hypersensitivity to any of the study medications, excipients or investigational device material or to medications of similar chemical classes, any history of drug hypersensitivity or other significant allergic diathesis that could affect study participation and known or suspected contraindications, including history of allergy or photosensitivity to study medication/s.
- Participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 30 days of the screening visit or 5 half-lives of enrollment, whichever is longer and previous participation in this study (i.e. participants cannot be re-screened or randomized). Recent history (within the last 5 years) of alcohol or other substance abuse and positive urine drug screen.
- An employee of the sponsor or the study sites or members of their immediate family and persons directly or indirectly involved in the execution of this protocol, including employees of the contract research organization (CRO) and persons related to them.
- On nasal examination by Investigator, the presence of nasal disease likely to affect deposition of intranasal treatment or any superficial or moderate nasal mucosal erosion, nasal mucosal ulceration, or nasal septum perforation at the screening visit. Participants with difficulty in using the nasal spray applicator, “vulnerable” individual (as defined by the IRB e.g. incarcerated person) and any condition not identified in the protocol that in the opinion of the Investigator would confound the evaluation and interpretation of the study data or may put the participant at risk.
Trial location(s)
Location
GSK Investigational Site
Anderson, South Carolina, United States, 29621
Status
Study Complete
Location
GSK Investigational Site
Bellevue, Washington, United States, 98004
Status
Study Complete
Location
GSK Investigational Site
Birmingham, Alabama, United States, 35211
Status
Study Complete
Location
GSK Investigational Site
Centennial, Colorado, United States, 80112
Status
Study Complete
Location
GSK Investigational Site
Chandler, Arizona, United States, 85224
Status
Study Complete
Location
GSK Investigational Site
Chicago, Illinois, United States, 60602
Status
Study Complete
Location
GSK Investigational Site
Cincinnati, Ohio, United States, 45249
Status
Study Complete
Location
GSK Investigational Site
Council Bluffs, Iowa, United States, 51503
Status
Study Complete
Location
GSK Investigational Site
Edina, Minnesota, United States, 55435
Status
Study Complete
Location
GSK Investigational Site
Elkhorn, Nebraska, United States, 68022
Status
Study Complete
Location
GSK Investigational Site
Hatboro, Pennsylvania, United States, 19040
Status
Study Complete
Location
GSK Investigational Site
Littleton, Colorado, United States, 80128
Status
Study Complete
Location
GSK Investigational Site
Pinellas Park, Florida, United States, 33781
Status
Study Complete
Location
GSK Investigational Site
Saint Louis, Missouri, United States, 63141
Status
Study Complete
Location
GSK Investigational Site
San Antonio, Texas, United States, 78229
Status
Study Complete
Location
GSK Investigational Site
Vista, California, United States, 92083
Status
Study Complete
Study documents
Statistical analysis plan
Available language(s): English
Protocol
Available language(s): English
Clinical study report
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2017-07-06
Actual study completion date
2017-07-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Safety and Efficacy of 0.5% Carbomer 980 Gel for Treatment of Symptoms of Common Cold: Results of 2 Randomized Trials.
Click hereAccess to clinical trial data by researchers
Visit website